Device Trial Radar · NCT07917221
Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Adults With Chronic Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Nov 18, 2026
Primary completion
May 18, 2027
Study completion Nov 18, 2027
Sponsor
- Lead sponsor
- Casa Colina Hospital and Centers for HealthcareAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Niche Biomedical, Inc. dba ANEUVO
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability, and feasibility of ExaStim transcutaneous electrical stimulation combined with task-specific rehabilitation, and to characterize changes in arm function in adults with chronic unilateral ischemic stroke. The main questions it aims to answer are: * Does 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation improve arm function? * What are the safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke? Participants will: * Complete a 12-week intervention period combining ExaStim transcutaneous electrical stimulation with structured, task-specific rehabilitation * Undergo clinical assessments and outcome testing baseline, week 4, week 8, week 12, and week 17 (follow-up) * Monitor and report pain and quality of life via Visual Analog Scales (VAS) and questionnaires throughout the 17-week study duration
Conditions
- Chronic Stroke
- Ischemic Stroke
- CVA (Cerebrovascular Accident)
Interventions
Transcutaneous Spinal StimulationDevice
Week 0 includes one baseline assessment session and two to three parameter optimization sessions. Participants will attend 2 rehabilitation sessions per week for 12 weeks, for a total of 24 sessions. Each session will provide \~60 minutes of rehabilitation, including at least 45 minutes of active stimulation delivered concurrently with therapeutic activity. The therapist will select activities according to participant goals, affected-arm capacity, movement quality, fatigue, pain, and cardiovascular tolerance. Each session will emphasize repeated practice, functional strength or functional practice. Missed sessions will be rescheduled within the 12-week period if appropriate. Separate assessment visits occur in Weeks 4, 8, 12, and 17 and may last approximately one to two hours with rest breaks. The final evaluation is scheduled for Week 17. All assessments will use the same participant-specific baseline date as the time reference, and actual visit dates and intervals will be recorded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fugl-Meyer Assessment for Upper Extremity - Motor Score (FMA-UE)Time frame: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Casa Colina Hospital and Centers for Healthcare
Pomona, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.